Ultimate magazine theme for WordPress.

BTC
$8,093.65
+1.38%
ETH
$257.07
+2.33%
LTC
$103.66
+6.5%
DASH
$158.55
+0.11%
XMR
$87.48
+1.71%
NXT
$0.03
0%
ETC
$7.37
+1.94%
DOGE
$0.00
+1.2%
ZEC
$73.81
-0.39%
BTS
$0.07
0%
DGB
$0.02
+3.41%
XRP
$0.39
+1.4%
BTCD
$20.33
PPC
$0.41
0%
CRAIG
$0.00
XBS
$2.00
XPY
$0.01
0%
PRC
$0.00
0%
YBC
$1,439.57
0%
DANK
$0.00

Pfizer Results Top Expectations

2,174

Pfizer (PFE) raised its full-year guidance for adjusted earnings on Tuesday as it posted better-than-expected results for its fiscal first quarter, which were supported by growth in its biopharmaceutical business.

- Advertisement -

The New-York headquartered company reported revenue of $13.1 billion in the three months ended March 31, up 2% from the corresponding quarter of the prior year. This was ahead of the consensus estimate of analysts polled by Capital IQ for $13 billion. Adjusted earnings per share came in at $0.85, up from $0.75 a year earlier and ahead of the Street’s forecast for $0.75.

Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it!

This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market…

You will also receive a free, weekly newsletter to stay on top of the latest industry trends, read analysis on promising cannabis stocks, and more. Click here to receive your Free Report immediately!

The results were supported by a 3% increase in sales from biopharma to $9.19 billion, which offset a 1% decline in Upjohn’s revenue to $3.08 billion. Upjohn is Pfizer’s off-patented branded and generic established medicine business. Sales within the consumer healthcare segment fell by 5% to $858 million.

Comments